Swedish medical technology group Vitrolife said on Thursday it would buy reproductive genetic testing services provider Igenomix S.L. in a deal worth 1.25 billion euros ($1.48 billion) on a cash and debt free basis.
The deal with private equity group EQT and other shareholders would be financed through a mix of shares issued to the sellers, a directed share issue to institutional investors, new debt and its own cash, Vitrolife said.
“The combination will create a global leader in reproductive health by combining the knowledge, product portfolios and market presence of two leading companies within IVF medical devices and reproductive genetic testing services,” it said in statement.
Can't stop reading? This and all news articles are property of their creators, many are not owned or provided by Private Equity Insider. As an event organizer and community platform, we curate content from reliable sources for your suggested reading, and advise you to read the full articles from the referenced authors and sources.